Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as ampoules, cartridges, vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and care and decorative cosmetics; and bottles and jars for spirits and food. The Advanced Technologies division develops drug delivery products and platforms, such as micro pumps, which are used to self-administer medication for diabetes or Parkinson's for pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in Düsseldorf, Germany.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+49-211-618100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.37 billion
Profitability
Miscellaneous
Employees9,890
Next Earnings Date7/11/2019 (Estimated)
OptionableNot Optionable
Gerresheimer (ETR:GXI) Frequently Asked Questions
What is Gerresheimer's stock symbol?
Gerresheimer trades on the ETR under the ticker symbol "GXI."
When is Gerresheimer's next earnings date?
What price target have analysts set for GXI?
12 Wall Street analysts have issued 1 year price objectives for Gerresheimer's stock. Their predictions range from €50.00 to €84.00. On average, they anticipate Gerresheimer's stock price to reach €69.17 in the next year. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Price Targets for Gerresheimer.
What is the consensus analysts' recommendation for Gerresheimer?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gerresheimer in the last year. There are currently 3 sell ratings, 6 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Gerresheimer.
Has Gerresheimer been receiving favorable news coverage?
Media coverage about GXI stock has been trending neutral this week, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Gerresheimer earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
Who are some of Gerresheimer's key competitors?
Some companies that are related to Gerresheimer include Ansell (ANN), Enerplus (ERF), RESMED/IDR UNRESTR (RMD), Nanosonics (NAN), Advanced Medical Solutions Group (AMS), TransEnterix (TRXC), Clover (CLV), CRH Medical (CRH), Bovie Medical (BVX), Bovie Medical (BVX), CRH Medical (CRHM), CRH Medical (CRHM), Tristel (TSTL), SDI (SDI) and InfuSystem (INFU).
What other stocks do shareholders of Gerresheimer own?
Who are Gerresheimer's key executives?
Gerresheimer's management team includes the folowing people:
- Mr. Dietmar Siemssen, CEO & Member of Management Board (Age 56)
- Mr. Rainer Beaujean, CFO & Member of the Management Board (Age 51)
- Dr. Lukas Burkhardt, Member of Management Board (Age 40)
- Ms. Katja Schnitzler, Group Director of Bus. Excellence & Continuous Improvement and Member of the Supervisory Board (Age 38)
- Ms. Severine Camp, Corp. Sr. Director of Investor Relations
What is Gerresheimer's stock price today?
One share of GXI stock can currently be purchased for approximately €66.05.
How big of a company is Gerresheimer?
Gerresheimer has a market capitalization of $2.07 billion and generates $1.37 billion in revenue each year. Gerresheimer employs 9,890 workers across the globe.
What is Gerresheimer's official website?
How can I contact Gerresheimer?
Gerresheimer's mailing address is Klaus-Bungert-Strasse 4, DUESSELDORF, 40468, Germany. The company can be reached via phone at +49-211-618100.
MarketBeat Community Rating for Gerresheimer (ETR GXI)
MarketBeat's community ratings are surveys of what our community members think about Gerresheimer and other stocks. Vote "Outperform" if you believe GXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
